Abstract

This paper addresses the fortunes of Biolyse, a small Canadian company, whose sole product for many years was an affordable version of the anticancer-drug, paclitaxel, derived from the yew tree. Repeated lawsuits and stringent regulations have made its survival precarious. The repeated attacks on this company demonstrate the travails of industrial innovation in confronting that other “crab” of big pharma. Sources include scientific publications, newspapers, interviews, and legal documents.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.